SilverCloud Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital mental health platform delivering evidence-based CBT programs, Dublin Ireland, acquired by Amwell, serves 500+ health systems and payers globally.
About
SilverCloud Health is a Dublin, Ireland-based digital mental health platform founded in 2012 at Trinity College Dublin. The company specializes in delivering structured, evidence-based cognitive behavioral therapy (CBT) programs through an asynchronous digital format supported by a trained human reviewer. SilverCloud was acquired by Amwell in 2021, integrating its digital mental health programs into Amwell's broader virtual care platform serving health systems, health plans, and employers.\n\nThe platform offers more than 20 condition-specific programs covering depression, anxiety, insomnia, chronic pain, diabetes, and workplace stress, among others. Each program is built on clinically validated CBT frameworks and follows a structured curriculum over six to eight weeks. Users work through modules independently and receive feedback and encouragement from a trained human supporter, a model known as supported self-management that has shown strong outcomes in peer-reviewed research.\n\nSilverCloud serves more than 500 health systems, insurers, and employers across the United Kingdom, Ireland, and the United States. Its clinical credibility is underpinned by a robust evidence base of over 90 published research studies, making it one of the most rigorously evaluated digital mental health interventions available. Following the Amwell acquisition, SilverCloud has expanded its reach through Amwell's existing hospital and health plan relationships.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.